D.A. Davidson & CO. purchased a new stake in Emergent Biosolutions Inc (NYSE:EBS) during the third quarter, HoldingsChannel.com reports. The firm purchased 3,408 shares of the biopharmaceutical company’s stock, valued at approximately $224,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Parametrica Management Ltd acquired a new position in shares of Emergent Biosolutions in the 3rd quarter valued at $223,000. Family Firm Inc. acquired a new position in shares of Emergent Biosolutions in the 3rd quarter valued at $225,000. Everence Capital Management Inc. acquired a new position in shares of Emergent Biosolutions in the 3rd quarter valued at $261,000. Thompson Siegel & Walmsley LLC acquired a new position in shares of Emergent Biosolutions in the 2nd quarter valued at $202,000. Finally, Sun Life Financial INC acquired a new position in shares of Emergent Biosolutions in the 2nd quarter valued at $234,000. Institutional investors own 81.39% of the company’s stock.

In other news, EVP Adam Havey sold 22,996 shares of the firm’s stock in a transaction on Tuesday, October 16th. The shares were sold at an average price of $61.06, for a total value of $1,404,135.76. Following the transaction, the executive vice president now owns 36,079 shares of the company’s stock, valued at approximately $2,202,983.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Sue Bailey sold 17,717 shares of the firm’s stock in a transaction on Tuesday, November 27th. The shares were sold at an average price of $69.62, for a total transaction of $1,233,457.54. Following the completion of the transaction, the director now directly owns 57,216 shares in the company, valued at approximately $3,983,377.92. The disclosure for this sale can be found here. In the last three months, insiders sold 163,678 shares of company stock worth $11,030,898. Insiders own 16.50% of the company’s stock.

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald set a $62.00 price target on shares of Emergent Biosolutions and gave the company a “buy” rating in a report on Tuesday, August 28th. Argus raised their target price on shares of Emergent Biosolutions to $70.00 and gave the company an “average” rating in a research note on Tuesday, September 11th. They noted that the move was a valuation call. Chardan Capital raised their target price on shares of Emergent Biosolutions from $60.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, September 4th. Cowen reissued a “hold” rating and issued a $49.00 target price on shares of Emergent Biosolutions in a research note on Wednesday, August 29th. Finally, Zacks Investment Research downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Monday, August 20th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $68.13.

Shares of EBS stock opened at $65.59 on Friday. Emergent Biosolutions Inc has a 52 week low of $42.50 and a 52 week high of $73.89. The company has a current ratio of 5.52, a quick ratio of 4.29 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $3.53 billion, a PE ratio of 29.72, a price-to-earnings-growth ratio of 1.61 and a beta of 1.26.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.55 EPS for the quarter, missing the Zacks’ consensus estimate of $0.62 by ($0.07). Emergent Biosolutions had a net margin of 14.19% and a return on equity of 12.89%. The business had revenue of $173.70 million during the quarter, compared to analysts’ expectations of $185.16 million. During the same period in the prior year, the business posted $0.73 EPS. The business’s revenue was up 16.3% on a year-over-year basis. On average, equities analysts expect that Emergent Biosolutions Inc will post 2.15 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “D.A. Davidson & CO. Purchases Shares of 3,408 Emergent Biosolutions Inc (EBS)” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/d-a-davidson-co-purchases-shares-of-3408-emergent-biosolutions-inc-ebs/2669596.html.

Emergent Biosolutions Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Read More: Can individual investors take part in an IPO?

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.